|
1
|
Kinch LN and Grishin NV: The human Ago2 MC
region does not contain an eIF4E-like mRNA cap binding motif. Biol
Direct. 4:22009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Z, Li Y, Ahmad A, et al: Targeting
miRNAs involved in cancer stem cell and EMT regulation: An emerging
concept in overcoming drug resistance. Drug Resist Updat.
13:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zimmerman AL and Wu S: MicroRNAs, cancer
and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medina PP and Slack FJ: microRNAs and
cancer: an overview. Cell Cycle. 7:2485–2492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Büssing I, Slack FJ and Grosshans H: let-7
microRNAs in development, stem cells and cancer. Trends Mol Med.
14:400–409. 2008.
|
|
7
|
Roush S and Slack FJ: The let-7 family of
microRNAs. Trends Cell Biol. 18:505–516. 2008. View Article : Google Scholar
|
|
8
|
Johnson CD, Esquela-Kerscher A, Stefani G,
et al: The let-7 microRNA represses cell proliferation pathways in
human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Muller DW and Bosserhoff AK: Integrin beta
3 expression is regulated by let-7a miRNA in malignant melanoma.
Oncogene. 27:6698–6706. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He XY, Chen JX, Ou-Yang X, Zhang Z and
Peng HM: Construction of let-7a expression plasmid and its
inhibitory effect on k-Ras protein in A549 lung cancer cells. Nan
Fang Yi Ke Da Xue Xue Bao. 30:2427–2431. 2010.(In Chinese).
|
|
12
|
Sureban SM, May R, Ramalingam S, et al:
Selective blockade of DCAMKL-1 results in tumor growth arrest by a
Let-7a MicroRNA dependent mechanism. Gastroenterology. 137:649–659.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oliveras-Ferraros C, Cufi S,
Vazquez-Martin A, et al: Micro(mi)RNA expression profile of breast
cancer epithelial cells treated with the anti-diabetic drug
metformin: induction of the tumor suppressor miRNA let-7a and
suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle.
10:1144–1151. 2011.PubMed/NCBI
|
|
14
|
Clevers H: The cancer stem cell: premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ito K, Bernardi R, Morotti A, et al: PML
targeting eradicates quiescent leukaemia-initiating cells. Nature.
453:1072–1078. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shachaf CM, Kopelman AM, Arvanitis C, et
al: MYC inactivation uncovers pluripotent differentiation and
tumour dormancy in hepatocellular cancer. Nature. 431:1112–1117.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Y, Deng C, Wang J, et al: Let-7
family miRNAs regulate estrogen receptor alpha signaling in
estrogen receptor positive breast cancer. Breast Cancer Res Treat.
127:69–80. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Charafe-Jauffret E, Ginestier C, Iovino F,
et al: Breast cancer cell lines contain functional cancer stem
cells with metastatic capacity and a distinct molecular signature.
Cancer Res. 69:1302–1313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iliopoulos D, Hirsch HA, Wang G and Struhl
K: Inducible formation of breast cancer stem cells and their
dynamic equilibrium with non-stem cancer cells via IL6 secretion.
Proc Natl Acad Sci USA. 108:1397–1402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goodell MA, Brose K, Paradis G, Conner AS
and Mulligan RC: Isolation and functional properties of murine
hematopoietic stem cells that are replicating in vivo. J Exp Med.
183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Challen GA and Little MH: A Side order of
dtem vells: the SP phenotype. Stem Cells. 24:3–12. 2006. View Article : Google Scholar
|
|
23
|
Ho MM, Ng AV, Lam S and Hung JY: Side
population in human lung cancer cell lines and tumors is enriched
with stem-like cancer cells. Cancer Res. 67:4827–4833. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hadnagy A, Gaboury L, Beaulieu R and
Balicki D: SP analysis may be used to identify cancer stem cell
populations. Exp Cell Res. 312:3701–3710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Geng S, Wang Q, Wang J, et al: Isolation
and identification of a distinct side population cancer cells in
the human epidermal squamous cancer cell line A431. Arch Dermatol
Res. 303:181–189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu X, Xu K, Lu H, et al: CD44(+)/CD24(−)
cells are transit progenitors and do not determine the molecular
subtypes and clinical parameters in breast carcinomas. Ultrastruct
Pathol. 35:72–78. 2011.
|
|
28
|
Wang J, Guo L-P, Chen L-Z, Zeng Y-X and Lu
SH: Identification of cancer stem cell-like side population cells
in human nasopharyngeal carcinoma cell line. Cancer Res.
67:3716–3724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakanishi T, Chumsri S, Khakpour N, et al:
Side-population cells in luminal-type breast cancer have
tumour-initiating cell properties, and are regulated by HER2
expression and signalling. Br J Cancer. 102:815–826. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi GM, Xu Y, Fan J, et al: Identification
of side population cells in human hepatocellular carcinoma cell
lines with stepwise metastatic potentials. J Cancer Res Clin Oncol.
134:1155–1163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dick JE: Stem cell concepts renew cancer
research. Blood. 112:4793–4807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bhattacharyya S and Khanduja KL: New hope
in the horizon: cancer stems cells. Acta Biochim Biophys Sin.
42:237–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Idowu MO, Kmieciak M, Dumur C, et al:
CD44(+)/CD24(−/low) cancer stem/progenitor cells are more abundant
in triple-negative invasive breast carcinoma phenotype and are
associated with poor outcome. Hum Pathol. 43:364–373. 2012.
|
|
34
|
Abraham BK, Fritz P, McClellan M,
Hauptvogel P, Athelogou M and Brauch H: Prevalence of
CD44+/CD24−/low cells in breast cancer may
not be associated with clinical outcome but may favor distant
metastasis. Clin Cancer Res. 11:1154–1159. 2005.PubMed/NCBI
|
|
35
|
Charafe-Jauffret E, Ginestier C, Iovino F,
et al: Aldehyde dehydrogenase 1-positive cancer stem cells mediate
metastasis and poor clinical outcome in inflammatory breast cancer.
Clin Cancer Res. 16:45–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiao X, Katiyar S, Willmarth NE, et al:
c-Jun induces mammary epithelial cellular invasion and breast
cancer stem cell expansion. J Biol Chem. 285:8218–8226. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chuthapisith S, Eremin J, El-Sheemey M and
Eremin O: Breast cancer chemoresistance: Emerging importance of
cancer stem cells. Surg Oncol. 19:27–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Silva IA, Bai S, McLean K, et al: Aldehyde
dehydrogenase in combination with CD133 defines angiogenic ovarian
cancer stem cells that portend poor patient survival. Cancer Res.
71:3991–4001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iinuma H, Watanabe T, Mimori K, et al:
Clinical significance of circulating tumor cells, including cancer
stem-like cells, in peripheral blood for recurrence and prognosis
in patients with Dukes’ stage B and C colorectal cancer. J Clin
Oncol. 29:1547–1555. 2011.PubMed/NCBI
|
|
40
|
Giovannetti E, Erozenci A, Smit J, Danesi
R and Peters GJ: Molecular mechanisms underlying the role of
microRNAs (miRNAs) in anticancer drug resistance and implications
for clinical practice. Crit Rev Oncol Hematol. 81:103–122. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sayed D and Abdellatif M: MicroRNAs in
development and disease. Physiol Rev. 91:827–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
